BIOMAT Database Logo BIOMAT Database Logo

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope. 2019

Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Department of Biochemistry and Molecular Pharmacology , University of Massachusetts Medical School , Worcester , Massachusetts 01605 , United States.

A structure-guided design strategy was used to improve the resistance profile of HIV-1 protease inhibitors by optimizing hydrogen bonding and van der Waals interactions with the protease while staying within the substrate envelope. Stereoisomers of 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene moieties were explored as P2' ligands providing pairs of diastereoisomers epimeric at P2', which exhibited distinct potency profiles depending on the configuration of the hydroxyl group and size of the P1' group. While compounds with the 4-(1-hydroxyethyl)benzene P2' moiety maintained excellent antiviral potency against a panel of multidrug-resistant HIV-1 strains, analogues with the polar 4-(1,2-dihydroxyethyl)benzene moiety were less potent, and only the (R)-epimer incorporating a larger 2-ethylbutyl P1' group showed improved potency. Crystal structures of protease-inhibitor complexes revealed strong hydrogen bonding interactions of both (R)- and (S)-stereoisomers of the hydroxyethyl group with Asp30'. Notably, the (R)-dihydroxyethyl group was involved in a unique pattern of direct hydrogen bonding interactions with the backbone amides of Asp29' and Asp30'. The SAR data and analysis of crystal structures provide insights for optimizing these promising HIV-1 protease inhibitors.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
November 2008, Organic letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
April 2006, Bioorganic & medicinal chemistry letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
September 2007, Journal of medicinal chemistry,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
June 2011, Bioorganic & medicinal chemistry letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.
September 2019, Bioorganic & medicinal chemistry letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
February 2010, Bioorganic & medicinal chemistry letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
March 1998, Bioorganic & medicinal chemistry letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
November 2004, Bioorganic & medicinal chemistry letters,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.
September 2013, Chemistry & biology,
Linah N Rusere, and Gordon J Lockbaum, and Sook-Kyung Lee, and Mina Henes, and Klajdi Kosovrasti, and Ean Spielvogel, and Ellen A Nalivaika, and Ronald Swanstrom, and Nese Kurt Yilmaz, and Celia A Schiffer, and Akbar Ali
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
December 2006, Journal of medicinal chemistry,
Copied contents to your clipboard!